Skip to main content
Cytogen, Inc. logo

Cytogen, Inc. — Investor Relations & Filings

Ticker · 217330 ISIN · KR7217330000 KO Manufacturing
Open in API
Filings indexed 437 across all filing types
Latest filing 2021-03-08 Proxy Solicitation & In…
Country KR South Korea
Listing KO 217330

About Cytogen, Inc.

https://www.cytogenlab.com/

Cytogen, Inc. is a biotechnology company specializing in liquid biopsy platforms for precision oncology. The company has developed proprietary technology for the rapid isolation and analysis of viable Circulating Tumor Cells (CTCs) from whole blood. Its core offering, the SmartBiopsy Platform, utilizes a high-density microporous chip with microfluidics and nanotechnology to capture CTCs efficiently. This non-invasive diagnostic approach is designed to support early cancer detection, treatment monitoring, and the advancement of personalized medicine for cancer patients.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Cytogen. It contains the agenda for the 11th Annual General Meeting, including financial statement approval, board appointments, and proposed amendments to the articles of incorporation. This document is a standard proxy statement/notice sent to shareholders to inform them of the meeting and solicit their votes, which falls under the Proxy Solicitation & Information Statement category.
2021-03-08 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used to provide shareholders with information regarding upcoming general meetings, including agenda items like director appointments, financial statement approval, and articles of incorporation changes. This document is specifically designed to solicit proxies for the Annual General Meeting (AGM). In the context of the provided filing categories, this fits the definition of a Proxy Solicitation & Information Statement (PSI).
2021-03-08 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is explicitly labeled as a '정정신고' (Correction Report). It details changes to previously reported stock option grants, including adjustments to the number of shares and the list of recipients due to resignations. This type of filing is a standard regulatory disclosure regarding capital structure and employee compensation, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes).
2021-03-05 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company CytoGen. It outlines the date, location, and specific agenda items for the upcoming Annual General Meeting (AGM), including the approval of financial statements, election of directors, and appointment of auditors. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and the matters to be voted upon.
2021-03-05 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (CytoGen) announcing a significant change (over 30%) in its financial structure (revenue, operating profit, net income) compared to the previous fiscal year. This type of disclosure is a standard regulatory requirement in the Korean market (DART system) for material financial changes. Since it provides specific financial highlights and reasons for the variance rather than being a full annual report or a simple announcement of a report's availability, it falls under the category of general regulatory filings. FY 2020
2021-02-18 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Services Commission and Korea Exchange. This type of filing is a standard regulatory requirement in South Korea for entities that acquire a significant stake (typically 5% or more) in a publicly traded company. It details the identity of the shareholder (Ascent Bio Fund), the number of shares held, the purpose of the holding (simple investment), and the history of transactions. This falls under the 'Major Shareholding Notification' category.
2021-02-17 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.